Top-News
Werbung
Attraktive Knock-Outs auf Johnson & Johnson Corp
Typ Hebel Bid / Ask WKN
Call
3,7 4,75 € / 4,76 €
SX4MJV
Typ Hebel Bid / Ask WKN
Put
5,6 3,19 € / 3,20 €
FD15UJ
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Johnson & Johnson Corp

Johnson & Johnson Aktie News

Aktie
WKN:  853260 ISIN:  US4781601046 US-Symbol:  JNJ Branche:  Pharmazeutika Land:  USA
209,30 $
+0,00 $
0,00%
178,44 € 01:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
434,32 Mrd. €
Streubesitz
24,80%
KGV
24,93
Dividende
1,30 $
Dividendenrendite
0,61%
neu: Nachhaltigkeits-Score
41 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,97: UQ0NZM
Werbung

Johnson & Johnson News

03.11.25 - dpa-AFX
ROUNDUP/Trotz Trump-Vorwürfen: Kimberly-Clark übernimmt Tylenol-Hersteller
Mitten in der vom Weißen Haus losgetretenen Kontroverse um das Schmerzmittel Tylenol und Autismus wird der Hersteller Kenvue vom Konsumgüter-​Riesen Kimberly-​Clark ...
03.11.25 - dpa-AFX
Trotz Trump-Vorwürfen: Kimberly-Clark übernimmt Tylenol-Hersteller
Mitten in der vom Weißen Haus losgetretenen Kontroverse um das Schmerzmittel Tylenol und Autismus wird der Hersteller Kenvue vom Konsumgüter-​Riesen Kimberly-​Clark ...
29.10.25 - PR Newswire
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Johnson & Johnson announces first head-​to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting PR ...
27.10.25 - PR Newswire
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile PR Newswire
27.10.25 - PR Newswire
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years PR ...
27.10.25 - PR Newswire
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-​daily pill through 28 weeks in ulcerative colitis PR Newswire
24.10.25 - PR Newswire
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies PR ...
24.10.25 - PR Newswire
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-​to-treat scalp and genital ...
19.10.25 - PR Newswire
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer PR Newswire
16.10.25 - PR Newswire
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-​free survival and overall survival versus standard of care PR Newswire
15.10.25 - LYNX Analysen
Johnson & Johnson: Solide Zahlen, stabiler Trend
Die Johnson & Johnson Aktie zeigt sich nach den Quartals­zahlen stabil. Der Trend bleibt intakt, und neue Impulse könnten das Chartbild weiter stärken. Jetzt vollständige Analyse ...
14.10.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Blickpunkt: Citigroup, Goldman Sachs, JPMorgan sowie Johnson & Johnson
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
10.10.25 - PR Newswire
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress PR Newswire
07.10.25 - PR Newswire
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-​daily pill PR Newswire
07.10.25 - PR Newswire
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ...
07.10.25 - PR Newswire
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM ...
29.09.25 - PR Newswire
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor PR ...
19.09.25 - PR Newswire
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen ...
19.09.25 - PR Newswire
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-​eligible patients with newly diagnosed ...
17.09.25 - PR Newswire
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Icotrokinra shows superiority to deucravacitinib in first reported head-​to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis PR Newswire

Newssuche

Videos

newspaper
16.12.25 -2,95%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »